{'fraction_non_alphanumeric': 0.029560201874549386, 'fraction_numerical': 0.009372746935832732, 'mean_word_length': 5.974874371859296, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
CORR Insights®: What Factors Are Associated with Treatment Outcomes of Japanese Patients with Clear Cell Chondrosarcoma?

Clear cell chondrosarcoma is a rare subtype of chondrosarcoma that comprises only 1% to 2% of all chondrosarcomas; since chondrosarcomas are themselves rare, very little is known about clear cell chondrosarcoma. Only few case series have evaluated patients with this disease [1, 4, 6]. In thismonth’sClinicalOrthopaedics and Related Research,Nakayama et al. [8] performed a retrospective, multicenter study on clear cell chondrosarcoma through the Japanese Musculoskeletal Oncology Group (JMOG), focusing on the patient and tumor characteristics, details of the diagnostic process, oncological outcomes, and related risk factors. In their study, the authors found that nearly one-third of the patients diagnosed with clear cell chondrosarcoma were initially misdiagnosed (29%; 10 of 35), and that core needle biopsy was especially susceptible to diagnostic error in patients with clear cell chondrosarcoma. The incorrect initial diagnoses in patients with clear cell chondrosarcoma were conventional chondrosarcoma, chondroblastic osteosarcoma, and benign chondroblastoma. The authors suggested wide resection in patients with initial inadequate surgery in order to minimize the likelihood of local recurrence, a finding that echoes suggestions from other work [5].